Blair William & Co. IL Sells 51,038 Shares of Dynavax Technologies Corporation $DVAX

Blair William & Co. IL cut its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 2.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,228,609 shares of the biopharmaceutical company’s stock after selling 51,038 shares during the period. Blair William & Co. IL owned 1.90% of Dynavax Technologies worth $22,130,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. raised its stake in shares of Dynavax Technologies by 236.9% in the third quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,710 shares during the last quarter. LSV Asset Management acquired a new position in shares of Dynavax Technologies in the 3rd quarter worth approximately $89,000. Osaic Holdings Inc. grew its position in Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 1,226 shares during the last quarter. Summit Global Investments acquired a new stake in Dynavax Technologies during the 3rd quarter valued at $113,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in Dynavax Technologies during the 2nd quarter valued at $121,000. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Price Performance

DVAX opened at $15.50 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The stock has a market capitalization of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97. The company’s 50 day simple moving average is $15.51 and its 200-day simple moving average is $12.32. Dynavax Technologies Corporation has a one year low of $9.20 and a one year high of $15.73.

Insider Buying and Selling

In other Dynavax Technologies news, COO David F. Novack sold 114,000 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total value of $1,782,960.00. Following the transaction, the chief operating officer directly owned 63,344 shares in the company, valued at approximately $990,700.16. This trade represents a 64.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, January 21st. William Blair lowered Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Finally, Wall Street Zen raised Dynavax Technologies to a “strong-buy” rating in a report on Saturday, February 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Dynavax Technologies has an average rating of “Reduce” and an average price target of $21.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.